Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
BMJ Case Rep ; 13(4)2020 Apr 15.
Article in English | MEDLINE | ID: mdl-32300035

ABSTRACT

Neurotoxicity from intrathecally administered chemotherapeutic drugs is frequent, particularly with some agents like methotrexate, which are more prone to developing adverse effects. Myelopathy ranks among the most frequently reported neurological entities; with the diagnosis being straightforward, after ruling out infectious, metabolic, autoimmune or paraneoplastic causes. Scarcity of cases precludes evidence-based recommendations for the management of these complications. The most common therapeutic approach consists of the suspension of chemotherapy, exclusion of infectious and neoplastic causes, with prompt administration of high-dose steroids. We report a 21-year-old patient with acute lymphoblastic leukaemia, who developed acute transverse myelitis and bilateral sensorineural hearing loss, after five rounds of intrathecal methotrexate and cytarabine. Although neurotoxicity from both agents has been documented, this combination has not been previously reported.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Hearing Loss, Bilateral/chemically induced , Hearing Loss, Sensorineural/chemically induced , Myelitis, Transverse/chemically induced , Neuromyelitis Optica/chemically induced , Diagnosis, Differential , Humans , Injections, Spinal , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL